Cellectis Unveils DNA Break-Free Genomic Editing Approach in Boston
Cellectis introduces new research on an epigenetic editing approach based on TALE at the annual conference of the American Society of Gene and Cell Therapy, from May 11 to 15 in Boston.
Introduction of Epigenetic Modulators Without Permanent DNA Modification
Cellectis presents research on epigenetic modulators based on TALE (TALEM) at the annual conference of the American Society of Gene and Cell Therapy, which will be held from May 11 to 15, 2026 in Boston, Massachusetts. This approach utilizes fusion proteins consisting of a TALE DNA-binding domain associated with functional domains that mediate epigenetic modifications. Unlike traditional gene editing tools, this method does not induce DNA breaks or changes to the DNA sequence, potentially offering a safer alternative for genome editing.
Results Achieved on Two Distinct Genes with Over 90% Reduction
Cellectis has developed a high-throughput screening system capable of quickly assembling and testing hundreds of TALEMs. This strategy was applied to two distinct genes: one highly expressed in hepatocytes and the other involved in dysfunction and exhaustion of T cells, a key challenge in cancer immunotherapy. In both cases, the approach achieved a reduction of more than 90% in gene activity, which remained stable throughout the study. The summary is published on the ASGCT website. The poster will be available on the Cellectis website on Wednesday, May 13, 2026, at 5 PM Eastern Time.
